Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • ascls.org
    • ascls.org

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society for Clinical Laboratory Science
  • ascls.org
    • ascls.org
  • My alerts
  • Log in
  • My Cart
American Society for Clinical Laboratory Science

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • Follow ASCLS on Twitter
  • Visit ASCLS on Facebook
  • Follow ASCLS on Instagram
  • RSS Feed
Research ArticleDialogue and Discussion

Bioterror Defense and Its Impact on the Clinical Laboratory

Isaac D Montoya
American Society for Clinical Laboratory Science April 2006, 19 (2) 68-69; DOI: https://doi.org/10.29074/ascls.19.2.68
Isaac D Montoya
College of Pharmacy, University of Houston, 3104 Edloe, Suite 330, Houston TX 77027-6022. (713) 439-0210.
PhD CHS CLS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: imontoya@uh.edu
  • Article
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

  1. Isaac D Montoya, PhD CHS CLS
    1. College of Pharmacy, University of Houston, 3104 Edloe, Suite 330, Houston TX 77027-6022. (713) 439-0210. (imontoya{at}uh.edu)

Extract

Top government and public health officials have reported that the United States' investment of $20 billion in bioterrorism preparedness since 2001 has left the US dolefully unprepared to respond to a bioterrorism attack. Critics such as Irwin Redlener from the National Center for Disaster Preparedness at Columbia University contend that bioterrorism preparedness programs are not operated in an effective manner, thus wasting billions of dollars.

Bioterrorism preparedness is the primary responsibility of the Department of Health and Human Services (DHHS). The department's responsibilities include stocking antibiotics, sharing information among laboratories and hospitals, and assisting communities in response in the event of an emergency. This is an overwhelming responsibility even for the federal government. While the government has made advances in addressing this responsibility, problems exist with some of these efforts. For example, a national stockpile of medical equipment and supplies has been amassed and can be delivered to any city within 12 hours of an attack. Unfortunately, once the cities receive the supplies they have not developed the infrastructure to deliver these supplies to their citizens in a time frame that would save lives. While the location and exact contents of the stockpile are secret, DHHS reports that there is enough smallpox vaccine for every US resident and enough antibiotics to treat 60 million people who might be exposed the most viral form of anthrax.

In 2003 President Bush announced an initiative titled Project BioShield. The project is a $5.6 billion research effort intended to spur the development of vaccines…

    INDEX TERMS
  • bioterrorism
  • clinical laboratory
  • © Copyright 2006 American Society for Clinical Laboratory Science Inc. All rights reserved.
PreviousNext
Back to top

In this issue

American Society for Clinical Laboratory Science: 19 (2)
American Society for Clinical Laboratory Science
Vol. 19, Issue 2
Spring 2006
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Society for Clinical Laboratory Science.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Bioterror Defense and Its Impact on the Clinical Laboratory
(Your Name) has sent you a message from American Society for Clinical Laboratory Science
(Your Name) thought you would like to see the American Society for Clinical Laboratory Science web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Bioterror Defense and Its Impact on the Clinical Laboratory
Isaac D Montoya
American Society for Clinical Laboratory Science Apr 2006, 19 (2) 68-69; DOI: 10.29074/ascls.19.2.68

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Bioterror Defense and Its Impact on the Clinical Laboratory
Isaac D Montoya
American Society for Clinical Laboratory Science Apr 2006, 19 (2) 68-69; DOI: 10.29074/ascls.19.2.68
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Hail and Farewell
  • Response to Fall 2011 Article: Clinical Molecular Testing: Subspecialty, Entry-level or Specialist Certification
  • A Rose by Any Other Name is a … Dandelion?
Show more Dialogue and Discussion

Similar Articles

Keywords

  • bioterrorism
  • Clinical Laboratory

© 2025 The American Society for Clinical Laboratory Science

Powered by HighWire